AC
LPCN icon

Armistice Capital’s Lipocine LPCN Stock Holding History

Armistice Capital’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-23,529
Closed -$1.22M – 47
2016
Q2 		$1.22M Buy
+23,529
New +$3.64M 0.46% 42
2015
Q3 		– Sell
-50,000
Closed -$7.29M – 40
2015
Q2 		$7.29M Buy
+50,000
New +$6.21M 2.62% 17

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Armistice Capital's LPCN Position: Q3 2016 in Review

Armistice Capital sold out of Lipocine (LPCN) in Q3 2016, closing a stake of 23,529 shares — an estimated $1.22M sold.

Armistice Capital first reported a position in LPCN in Q2 2015 and held it in 2 quarters. The position peaked at $7.29M in Q2 2015. 47 funds tracked by Wall St. Rank hold LPCN as of Q3 2016.

  • Armistice Capital reported no remaining Lipocine position as of Q3 2016 after selling out during the quarter.
  • Armistice Capital sold 23,529 Lipocine shares in Q3 2016, an estimated $1.22M.
  • Armistice Capital first reported a position in Lipocine in Q2 2015 and held it in 2 quarters.
  • Armistice Capital's Lipocine position peaked at $7.29M in Q2 2015.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q3 2016.

Based on Armistice Capital's 13F filing for Q3 2016, filed 14 Nov 2016.